Skinbiotherapeutics’ Dr. Catherine O’Neill discusses passing third party cytotoxicity tests, their scientific update to the market & what’s next for the company in this exclusive interview with DirectorsTalk
SkinBioTherapeutics plc (LON:SBTX) a life sciences company focused on skin health, has announced its full year results for the year to 30 June 2017. Key highlights — Research agreement with
SkinBioTherapeutics plc LON:SBTX, a life science company focused on skin health, has passed third party cellular toxicity tests for its SkinBiotix(R) technology, confirming previous in-house observations on its safety and applicability.
SkinBioTherapeutics PLC (LON:SBTX) a life science company focused on skin health, will publish its full year results for the year to 30 June 2017 on Thursday, 5 October 2017.
“Love your bacteria.” That’s the tagline for Yun Probiotherapy’s line of skin cosmetics directed at those who have acne or athlete’s foot or who just want to keep their skin
Skinbiotherapeutics PLC (LON:SBTX) a life science company focused on skin health, has been nominated as a finalist in the Life Science IPO of the Year category of the Biotech and
Made in the UK is a celebration of the diverse sectors of our manufacturing, design and scientific sectors that make Britain a global centre of innovation. Now in its fourth year,
SkinBioTherapeutics Plc (LON:SBTX) CEO Dr Catherine O’Neill talks to DirectorsTalk about the extension of a contract with the University of Manchester. Catherine explains the purpose and audience of SkinBiotix, how
SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, has told DirectorsTalk that, as envisaged in the Company’s Admission Document dated 29 March 2017, it has agreed an
SkinBioTherapeutics PLC (LON:SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM at 8:00am yesterday under the ticker
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
